Every recall we track for Imprimis NJOF, LLC — 21 in all — plus the complaints and injury reports the public filed about them.
Imprimis recalls Dexamethasone Moxifloxacin eye injections due to glass particles. These injections are for prescription use only and may cause injury if particles enter the eye.
Imprimis NJOF recalls Dexamethasone Moxifloxacin Ketorolac intraocular injections due to glass particles. Stop using immediately to avoid eye injury.
Imprimis recalls Tri-Moxi+ eye injections due to glass particles. Stop using if you have the specific lot numbers listed. Contact for details.
Imprimis NJOF recalls specific lots of Klarity-C Cyclosporine eye drops due to subpotent drug levels. This compounded medication requires immediate action for safety.
Imprimis NJOF recalls epinephrine vials with subpotent assay results from stability testing. These vials may not contain enough active ingredient for effective treatment. Contact for details.
Imprimis recalls specific ophthalmic solution due to subpotent drug levels. This may not work as intended for eye treatments. Check your product details to see if affected.
Imprimis recalls ophthalmic solution with subpotent drug levels. Product may not work as intended. Check NDC 71384-733-05 and lot 24OCT041 for affected items.
Imprimis recalls specific epinephrine-lidocaine vials for intraocular use due to lack of sterility assurance. These vials may cause infection if used improperly.
Imprimis NJOF recalls Klarity-C (cyclosporine) eye drops due to lack of sterility assurance. This compounded drug may cause infection if used. Stop using and contact your doctor.
Imprimis recalls specific lots of Dexamethasone-Moxifloxacin eye injection vials due to lack of sterility assurance. These vials are for intraocular use only and may cause infection if used.
Imprimis NJOF recalls specific lots of moxifloxacin eye injection vials due to lack of sterility assurance. This could lead to infections if used improperly. Check your NDC and expiration dates.
Imprimis NJOF recalls prednisolone-moxifloxacin-bromfenac sterile eye drops (1%, 0.5%, 0.075%) with risk of contamination. Product was compounded by Imprimis NJOF, LLC in New Jersey. No remedy specified in recall notice.
Imprimis NJOF recalls specific epinephrine-lidocaine vials for assay inaccuracies. These prescription-only vials may not contain the correct medication concentration.
Imprimis recalls epinephrine-lidocaine eye injections due to potential underactive epinephrine. Affected lots may not work properly during eye procedures. Contact FDA for adverse events.
